Loading…
← CockpitCompetitor Analysis › BRVE Braveheart Bio, Inc.Open in the cockpit ↗

Braveheart Bio, Inc.BRVECompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Recently listed biotechnology company; specific pipeline and disease focus not confidently known.

Mkt cap
$1.67B
US dollars, full cap
Free float
23%
of shares outstanding
$/day
$9.42M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-41.3 pp
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$18.53
1D-1.3%
1W-11.3%
1M-8.6%
3M-32.4%
6Mn/a
YTDn/a
1Yn/a
ATR %8.8%
52w lowhigh42.1% off high

What Braveheart Bio does

Recently listed biotechnology company; specific pipeline and disease focus not confidently known.

Where it sits in the supply chain

  • Pharmaceuticals
  • Clinical-stage biotech

Moat: none

Braveheart Bio at a glance

Size Braveheart Bio (BRVE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.67B, the 1894th largest of 3,085 United States companies the cockpit tracks. Shares closed at $18.53 on 18 Nov 2026.

Capital Return on invested capital runs 41.3 points below its cost of capital (6.6% WACC).

Short interest Short interest is 5.7% of the free float (30 Oct 2026).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Braveheart Bio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025
Revenuen/a$0
Revenue growth——
Gross profitn/a$0
EBITDAn/a-$65.4M
Net incomen/a-$66.1M
Free cash flown/a-$2.01M
Capital expendituren/a$0
Total debt$515,000$0

Quarterly statements and history in the cockpit →

Braveheart Bio competitors and peer comparison

How Braveheart Bio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Braveheart Bio against its 20 peers (data as of 18 Nov 2026)
MeasureBRVEPeer medianRank in peer set
1-month return-8.6%-3.2%6th lowest of 21
Distance from 52-week high-42.1%-34.3%6th lowest of 21
ROIC minus cost of capital-41.3 pp-1.0 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%8.9×18.4%+10.8%
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%2.2×-14.9%+13.5%
Indegene INDGN.NSIndia$1.69B+28%+36%12%3.6×31.4%+29.4%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%2.3×-3.5%+6.8%
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%6.3×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%16.7×11.3%-11.0%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%2.6×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%68.8×n/an/a
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%12.2×33.0%+0.9%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%9.7×35.3%+9.2%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%5.6×42.4%+23.0%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%7.2×n/an/a
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%5.1×20.5%+19.0%
Sino Biological 301047.SZChina$1.60B+27%+20%17%9.8×31.1%-15.1%
Beijing Aosaikang Pharmaceutical 002755.SZChina$1.60B-31%-13%12%5.2×12.8%-14.0%
Shanghai Shyndec Pharmaceutical 600420.SSChina$1.59B-14%-13%6%1.2×-6.6%-5.6%
Jubilant Pharmova JUBLPHARMA.NSIndia$1.59B-8%+18%7%2.0×n/an/a
Yantai Dongcheng Biochemicals 002675.SZChina$1.59B0%-4%15%4.5×6.0%-4.3%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%2.5×n/an/a
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%8.3×n/an/a

Questions

Which companies are Braveheart Bio's closest peers?
The cockpit's peer set: Zhejiang Wolwo Bio-Pharmaceutical (300357.SZ), Consun Pharmaceutical (1681.HK), Indegene (INDGN.NS), Mayinglong Pharmaceutical (600993.SS), Caplin Point Laboratories (CAPLIPOINT.NS), ApicHope Pharmaceutical (300723.SZ), Faes Farma (FAE.MC), Maze Therapeutics (MAZE).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.